This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, congenital haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII  deficiency, and Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions or where platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.1,2

Reference not found
Reference not found
Reference not found
Reference not found
Reference not found
Reference not found
Reference not found

1.

NovoSeven® Summary of Product Characteristics.

2.

Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

3.

Say et al. Lancet Glob Health. 2014;2(6):e323-33.

4.

Bienstock et al. N Engl J Med 2021;384:1635-45.

5.

SCASMM 10th Annual Report 2012.

6.

MBRRACE-UK Maternal Deaths and Morbidity 2017-2019.

7.

Sentilhes, B et al. Exp Rev of Hem. 2016; 9:11, 1043-1061.

8.

Glover P. Aust J Midwifery 2003;16(2)21–4; 2. (Image obtained from) Bose P et al. BJOG 2006;113(8):919–24.

9.

Carroli G et al., “Epidemiology of Post Partum Haemorrhage: a systematic review”. Best Practice & Research Clinical Obstetrics and Gynaecology. Vol. 22, No. 6, pp. 999–1012, 2008.

10.

Munoz et al. NATA consensus, Blood Transfus 2019.

11.

WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrage. 2012.

12.

ACOG Practice Guidelines. Clinical Management Guidelines for Obstetrician-Gnecologists. Practice Bulletin 2017; 183 (4): e168-186.

13.

Zhang et al. Medicine (Baltimore). 2017;96(45):e8443.

14.

Christopoulos et al. J Obstet Gynaecol. 2011;31(2):139-41.

15.

Machado et al. N Am J Med Sci. 2011;3(8):358-61.

16.

Michelet et al. Gynecol Obstet Fertil. 2015;43(12):773-9.

17.

Sihler et al. Chest. 2010;137(1):209-20.

18.

Taylor et al. Transfus Altern Transfus Med. 2008;10(3):112-26.

19.

Thurn et al. Thrombosis Research 165 (2018) 54–60.

20.

Ramler et al. BMC Pregnancy Childbirth. 2017;17(1):197

21.

Callaghan WM et al. Am J Obstet Gynecol 2010;202(4):353.e1–6.

22.

Silver RM et al. Obstet Gynecol 2006;107(6):1226–32.

23.

Evensen A et al. Am Fam Physician 2017; 1;95(7):442–9.

24.

Adapted from NSW Ministry of Health. Postpartum haemorrhage (PPH). Guideline. 2021. Available from: https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2021_017.pdf. Accessed November 2021.

25.

Hers I et al. Platelets 2008;19(8):571–581.

26.

Kjalke M et al. Br J Haematol 2001;114(1):114–120.

27.

Lisman T et al. Blood 2004;103(5):1720–1727.

28.

Weeterings C et al. Blood 2008;112(8):3227–3233.

29.

Maahs J et al. J Blood Med. 2014;5:153-156.

30.

G. Lavigne-Lissalde et al. J of Thrombosis & Haemostasis, 13: 520-529; 2015.

31.

Rexen P et al. TH Open 2019;3:e45–e49.

32.

Pollard D et al. J Haem Pract 2017;4(1):1–5.

33.

FEIBA® Summary of Product Characteristics.

34.

Neufeld EJ et al. Blood Rev 2015;29(S1):S34–S41.

35.

Santagostino E et al. Thromb Haemost 2006;4(2):367–371.

36.

Neufeld EJ et al. Pediatr Blood Cancer 2013;60(7):1178–1183.

37.

Pruthi RK et al. Thromb Haemost 2007;98(4):726–732.

38.

Shapiro AD et al. Thromb Haemost 1998;80(5):773–778.

39.

Parameswaran R et al. Haemophilia 2005;11(2):100–106.

40.

Hay CR et al. Thromb Haemost 1997;7(8):1463–1467.

41.

Amano K et al. Haemophilia 2016;23(1):50–58.

42.

Baudo F et al. Blood 2012;120(1):39–46.

43.

Borel-Derlon A et al. Haemophilia 2016;22 Suppl 4:3–138. Poster PO-W-4.

44.

Sumner MJ et al. Haemophilia 2007;13(5):451–461.

45.

Lentz SR et al. J Blood Med 2014;5:1–3.

46.

Sun B et al. Br J Haematol 2019. doi: 10.1111/bjh.16128. [Epub ahead of print].

47.

Pardos-Gea J et al. Haemophilia 2018;24(3):e163–e166.

48.

Tiede A, Worster A. Ann Hematol 2018;97(10):1889–1901.

49.

Abshire T, Kenet G. Haemophilia 2008;14(5):898–902.

50.

Hedner U. Blood Rev 2015;29(S1):S4–S8.

51.

Hemlibra® Summary of Product Characteristics.